EGFR and non-small cell lung carcinoma: By using a decision-analytic model, one Singaporean study evaluated the economic outcome of gefitinib treatment for advanced NSCLC patients with activating EGFR mutations, which showed EGFR testing combined with first-line gefitinib treatment was a superior strategy to standard care due to lower costs and greater health benefits [17].